Summary
Boston Scientific Corporation (BSX) announced on June 19, 2008, that it has entered into a definitive agreement to sell a portfolio of its investments to Saints Capital, a secondary direct-investment firm. This strategic divestiture is expected to generate pre-tax proceeds exceeding $100 million, primarily in cash, with a portion structured as a multi-year note. This transaction is intended to streamline the company's investment portfolio and potentially provide capital for core operations or other strategic initiatives. As a direct consequence of this divestiture, Boston Scientific will recognize a material impairment charge. The company anticipates recording a net pre-tax loss of approximately $60 million (or $40 million after-tax, impacting earnings per share by roughly $0.03). This loss is composed of an approximate $85 million pre-tax loss expected in the second quarter of 2008, which will be partially offset by anticipated gains of $25 million later in the fiscal year. Investors should note that while this impairment charge reflects a negative impact on current earnings, the sale itself represents a move to potentially refocus resources and improve the overall financial structure.
Key Highlights
- 1BSX is selling a portfolio of investments to Saints Capital for over $100 million in pre-tax proceeds.
- 2The majority of proceeds will be in cash, with a portion financed by a note payable over several years.
- 3A net pre-tax impairment loss of approximately $60 million ($40 million after-tax) is expected due to the sale.
- 4The impairment charge will reduce diluted earnings per share by approximately $0.03.
- 5An estimated pre-tax loss of $85 million is anticipated for the second quarter of 2008 from this transaction.
- 6Offsetting gains of $25 million are expected in the remainder of 2008.
- 7The transaction is subject to certain closing conditions.